Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 120 participants.
Also called NCT02675790
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT02675790
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Nigeria
- Registry status
- Completed
Technical summary
Registry record NCT02675790. Randomized; quadruple masking; primary purpose prevention. Start 2017-01 (actual); primary completion 2020-03-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
- Acronym
- SPRINT
- Condition
- Sickle Cell Disease
- Condition
- Sickle Cell Anemia
- Condition
- Stroke
- Intervention (Drug)
- Moderate Dose Hydroxyurea
- Intervention (Drug)
- Low Dose Hydroxyurea
- Lead sponsor
- Vanderbilt University Medical Center
- Collaborator
- Aminu Kano Teaching Hospital
- Collaborator
- Murtala Muhammed Specialist Hospital
Record details
- Record id
cardio:ct-nct02675790- Content hash
a6a2f50bb4baa9f434c14e1bccb94641c935f71a1fd15c1e7c8d1b724fca7722